Micron Biomedical, an Atlanta, GA-based life science company developing a needle-free technology for drugs and vaccines that is based on dissolvable microarrays, raised $16m extending its Series A funding to over $33M.
The latest round was led by J2 Ventures and the Global Health Investment Corporation (GHIC).
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Steve Damon, Micron Biomedical specializes in dissolvable microarray-based, drug and vaccine administration technology. Its proprietary dissolvable, microarray technology technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance.
FinSMEs
16/01/2025